Efficacy of Antibiotic Eradication Therapy of Early Pseudomonas aeruginosa Infection in Children with Primary Ciliary Dyskinesia.

Abstract

Rationale: Chronic infection with Pseudomonas aeruginosa (PsA) negatively impacts lung disease in patients with primary ciliary dyskinesia (PCD). There is currently limited evidence regarding the efficacy of PsA antibiotic eradication therapy (AET) in children with PCD. Objectives: To assess the effectiveness of AET of early PsA infection in children with PCD. Methods: This retrospective study included pediatric patients with a confirmed PCD diagnosis according to the American Thoracic Society guidelines at the Hospital for Sick Children between 2010 and 2022. Children with newly acquired PsA infection underwent AET using a stepwise protocol. The protocol included the following steps: step 1, 28 days of tobramycin inhalation solution (TIS); step 2, repeat TIS if culture positive after step 1; and step 3, 14 days of intravenous antibiotics followed by 28 days of TIS if culture positive after step 2. Step 3 was also used for patients who presented with pulmonary exacerbation symptoms. The main outcome was a PsA-negative culture result based on the microbiological results of the first culture after completion of each step of treatment. Results: During the study period, 31 children had a new PsA infection and underwent AET. Of the 27 children who had been asymptomatic at the time of the PsA infection, negative PsA culture results were achieved in 20 (74%) of 27, 1 (14%) of 7, and 5 (83%) of 6 after steps 1, 2, and 3 of AET, respectively. All four symptomatic patients who initially were treated with step 3 had successful clearance of PsA. The overall cumulative success rate of the protocol for negative culture results after AET was 97% (30 of 31). For patients in whom AET was successful, the probability of staying PsA free for at least 1 year was 70%. Conclusions: AET for early PsA infection is highly effective in PCD, with sustained efficacy in most individuals. These data suggest that AET should be considered in all children with PCD who have early PsA infection.

• Authors: Dvir Gatt, Michelle Shaw, Wallace Wee, Melinda Solomon, Sharon D Dell, Felix Ratjen
• Journal: Annals of the American Thoracic Society (Ann Am Thorac Soc) Vol. 20 Issue 6 Pg. 854-860 (06 2023) ISSN: 2325-6621 [Electronic] United States
• PMID: 36753426 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Tobramycin

Topics

• Child
• Humans
• Pseudomonas Infections (complications, drug therapy, diagnosis)
• Retrospective Studies
• Cystic Fibrosis (drug therapy)
• Arthritis, Psoriatic (drug therapy)
• Anti-Bacterial Agents (therapeutic use)
• Tobramycin
• Pseudomonas aeruginosa
• Ciliary Motility Disorders